Mucosolvan (Ambroxol Hydrochloride)

Ambroxol acts by stimulating the production of surfactant in the airways, enhancing the activity of cilia, and breaking down the mucopolysaccharide fibers that give mucus its thickness. These actions collectively lower mucus viscosity, making it easier to transport and expel, which facilitates clearer breathing in patients with mucus‑related respiratory disorders.

The appropriate dose of Mucosolvan is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Physicians tailor the regimen to achieve optimal mucus clearance while minimizing potential side effects, and patients should follow the specific instructions provided on the prescription label.

Safety data for Ambroxol during pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any unknown risks before prescribing Mucosolvan to pregnant or breastfeeding women. It is essential to discuss individual circumstances with a qualified clinician to make an informed decision.

To order Mucosolvan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assists with import documentation.

Both Ambroxol (Mucosolvan) and acetylcysteine are mucolytics, but they differ in mechanism and tolerability. Ambroxol primarily stimulates surfactant production and ciliary activity, while acetylcysteine directly cleaves disulfide bonds in mucus proteins. Clinically, Ambroxol is often better tolerated with fewer gastrointestinal side effects, whereas acetylcysteine may cause a strong sulfurous odor and more frequent nausea.

Mucosolvan should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Mucosolvan is administered orally, typically as a tablet or liquid formulation, according to the prescribing clinician’s instructions. The dose is taken with or without food, and patients should swallow tablets whole with water or measure liquid doses accurately using a calibrated device.

The most serious risks include allergic reactions such as urticaria, angioedema, or anaphylaxis, as well as rare severe skin conditions like Stevens‑Johnson syndrome. Any signs of hypersensitivity, such as swelling of the face or difficulty breathing, require immediate medical attention.

Mucosolvan should be avoided in individuals with known hypersensitivity to ambroxol or any excipients in the formulation. Patients with severe hepatic impairment, uncontrolled asthma, or those taking medications that may cause dangerous interactions should consult a healthcare professional before use.